Objective: The study intent was to examine long-term effects on bone mass of 3 or 6 months of nafarelin therapy for endometriosis.
Study Design: Women with established endometriosis (N = 173) were randomized to receive nafarelin (200 micrograms intranasally twice a day) for either 3 or 6 months in a double-blind fashion. Bone mineral density was measured by dual energy x-ray absorptiometry at lumbar spine and proximal femoral sites for 18 months.
Results: Bone mineral density declined at spinal and femoral sites similarly in both 3- and 6-month treatment groups. There was a partial, but incomplete, return to baseline levels after 12 to 15 months of follow-up. The recovery of bone mass was more complete in subjects with higher dietary calcium intakes.
Conclusion: Nafarelin therapy for endometriosis results in a sustained loss of spinal and femoral bone density, particularly in women with lower calcium intakes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0002-9378(94)90136-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A study on the efficacy and safety of long-term adjusted low-dose gonadotropin-releasing hormone agonist therapy for uterine fibroids and adenomyosis.
J Obstet Gynaecol Res
December 2024
Department of Obstetrics and Gynecology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Aim: To investigate the efficacy and safety of long-term adjusted low-dose gonadotropin-releasing hormone agonist therapy (GnRH agonist drawback therapy) with nafarelin acetate in patients with uterine fibroids and/or adenomyosis with menstrual symptoms.
Methods: This single-center, retrospective, observational study initially included 118 patients with uterine fibroids and/or adenomyosis with menstrual symptoms who had received GnRH agonist (nafarelin acetate) drawback therapy for at least 7 months between 2010 and 2020. Blood hemoglobin level, maximum fibroid diameter, area of the corpus uteri, blood estradiol level, daily dosage of nafarelin acetate, and bone density in the lumbar spine and femoral neck were assessed before and after the treatment initiation.
Mitigating the economic burden of GnRH agonist therapy for progestogen-resistant endometriosis: why not?
Hum Reprod Open
March 2023
Department of Clinical Sciences and Community Health, Università degli Studi, Milano, Italy.
Study Question: Is it possible to reduce the cost of GnRH agonist treatment for endometriosis by using non-standard dosing regimens?
Summary Answer: An extended-interval dosing regimen of a 3.75 mg depot formulation of triptorelin injected every 6 weeks instead of every 4 weeks reduces the cost by one-third without compromising the effect on pain relief.
What Is Known Already: Cost constitutes a limit to prolonged GnRH agonists use.
"Flexible-Acceptor" General Solubility Equation for beyond Rule of 5 Drugs.
Mol Pharm
October 2020
Retired, Freiburg im Breisgau 79111, Germany.
This study describes a novel nonlinear variant of the well-known Yalkowsky general solubility equation (GSE). The modified equation can be trained with small molecules, mostly from the Lipinski Rule of 5 (Ro5) chemical space, to predict the intrinsic aqueous solubility, , of large molecules (MW > 800 Da) from beyond the rule of 5 (bRo5) space, to an accuracy almost equal to that of a recently described random forest regression (RFR) machine learning analysis. The new approach replaces the GSE constant factors in the intercept (0.
View Article and Find Full Text PDFGnRHa for trigger and luteal phase support in natural cycle frozen embryo transfer - A proof of concept study.
Reprod Biol
September 2020
The Fertility Center from A to Z, Affiliated with Assuta Medical Center, Tel Aviv, Israel; The Sackler Faculty of Medicine, Tel Aviv University, P.O.B 39040, Tel Aviv, Israel. Electronic address:
We aimed to explore whether ovulation induced by a GnRH analogue (GnRHa), followed by daily GnRHa luteal support provides an efficient platform for natural cycle frozen embryo transfer (NC-FET). In this cohort study, included were normo-ovulatory women who underwent NC-FET cycles, under the age of 40, with an antral follicle count > eight. Ovulation was triggered with triptorelin (0.
View Article and Find Full Text PDFElagolix (Orilissa)--an oral GnRH antagonist for endometriosis pain.
Med Lett Drugs Ther
September 2018
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!